Enhanced Pharmaceutical Composition for Cancer Treatment

An improved pharmaceutical composition for cancer treatment comprising a fusion protein dimer of CD80 and IL-2, and an anticancer agent, with enhanced stability, bioavailability, and immune response.

The original patent disclosed a pharmaceutical composition for cancer treatment, but it had limitations in terms of stability, bioavailability, and immune response. The new inventive concept addresses these limitations by modifying the fusion protein dimer to enhance its stability and bioavailability, and by using sustained-release formulations and targeted therapies to improve treatment outcomes.

The new inventive concept comprises a fusion protein dimer of CD80 and IL-2, which is modified to enhance its stability and bioavailability. The fusion protein dimer is administered with an anticancer agent, which can be selected from a group of targeted therapies. The pharmaceutical composition can be administered via a sustained-release formulation to improve treatment outcomes. Additionally, the new inventive concept includes a system for monitoring the efficacy of the pharmaceutical composition, which comprises a biomarker for tracking immune response. The new inventive concept also includes a method for enhancing the immune activity of the pharmaceutical composition by co-administering an immune checkpoint inhibitor.

The new inventive concept is novel and non-obvious compared to the original patent because it provides a modified fusion protein dimer with enhanced stability and bioavailability, and it uses sustained-release formulations and targeted therapies to improve treatment outcomes. The new inventive concept also includes a system for monitoring the efficacy of the pharmaceutical composition and a method for enhancing the immune activity of the pharmaceutical composition, which are not disclosed in the original patent.

Alternative embodiments of the new inventive concept include using different types of anticancer agents, such as chemotherapy drugs or hormone therapy drugs, and using different types of sustained-release formulations, such as nanoparticles or liposomes. Additionally, the new inventive concept can be used in combination with other cancer treatments, such as radiation therapy or surgery.

The new inventive concept has significant commercial potential in the cancer treatment market, which is expected to grow significantly in the coming years. The new inventive concept can be used to treat various types of cancer, including solid tumors and hematological malignancies. The target industries for the new inventive concept include pharmaceutical companies, biotechnology companies, and hospitals and clinics.